Which has stronger valuation and earnings, IMNM or CRMD?

CorMedix has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunome $6.94M 303.20 -$212.39M -$2.38 N/A CorMedix $311.71M 2.10 $163.05M $2.13 3.92

Is IMNM or CRMD more profitable?

CorMedix has a net margin of 45.25% compared to Immunome's net margin of 0.00%. CorMedix's return on equity of 45.57% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% CorMedix 45.25% 45.57% 24.76%

CorMedix (CRMD) Competitors

$8.36 -0.18 (-2.11%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$8.32 -0.04 (-0.44%)

As of 06/5/2026 07:56 PM Eastern

Compare

CRMD vs. MLYS, IDYA, TARS, VERA, and IMNM

Should you buy CorMedix stock or one of its competitors? MarketBeat compares CorMedix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CorMedix include Mineralys Therapeutics (MLYS), IDEAYA Biosciences (IDYA), Tarsus Pharmaceuticals (TARS), Vera Therapeutics (VERA), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry.

How does CorMedix compare to Mineralys Therapeutics?

CorMedix (NASDAQ:CRMD) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

In the previous week, Mineralys Therapeutics had 8 more articles in the media than CorMedix. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 0 mentions for CorMedix. Mineralys Therapeutics' average media sentiment score of 0.66 beat CorMedix's score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CorMedix	Neutral
Mineralys Therapeutics	Positive

CorMedix has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

CorMedix has a net margin of 45.25% compared to Mineralys Therapeutics' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

CorMedix has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.10	$163.05M	$2.13	3.92
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

34.2% of CorMedix shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CorMedix presently has a consensus price target of $15.00, suggesting a potential upside of 79.43%. Mineralys Therapeutics has a consensus price target of $49.33, suggesting a potential upside of 108.25%. Given Mineralys Therapeutics' higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

CorMedix beats Mineralys Therapeutics on 9 of the 14 factors compared between the two stocks.

How does CorMedix compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

IDEAYA Biosciences presently has a consensus price target of $50.69, indicating a potential upside of 79.17%. CorMedix has a consensus price target of $15.00, indicating a potential upside of 79.43%. Given CorMedix's higher probable upside, analysts plainly believe CorMedix is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

CorMedix has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	11.36	-$113.70M	-$1.60	N/A
CorMedix	$311.71M	2.10	$163.05M	$2.13	3.92

IDEAYA Biosciences has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

CorMedix has a net margin of 45.25% compared to IDEAYA Biosciences' net margin of 0.00%. CorMedix's return on equity of 45.57% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
CorMedix	45.25%	45.57%	24.76%

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, IDEAYA Biosciences had 6 more articles in the media than CorMedix. MarketBeat recorded 6 mentions for IDEAYA Biosciences and 0 mentions for CorMedix. IDEAYA Biosciences' average media sentiment score of 0.00 beat CorMedix's score of 0.00 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
IDEAYA Biosciences	Neutral
CorMedix	Neutral

Summary

CorMedix beats IDEAYA Biosciences on 9 of the 16 factors compared between the two stocks.

How does CorMedix compare to Tarsus Pharmaceuticals?

CorMedix (NASDAQ:CRMD) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 3.5% of CorMedix shares are owned by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CorMedix currently has a consensus price target of $15.00, suggesting a potential upside of 79.43%. Tarsus Pharmaceuticals has a consensus price target of $90.67, suggesting a potential upside of 52.95%. Given CorMedix's higher probable upside, equities research analysts clearly believe CorMedix is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

CorMedix has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

CorMedix has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.10	$163.05M	$2.13	3.92
Tarsus Pharmaceuticals	$451.36M	5.65	-$66.42M	-$1.14	N/A

CorMedix has a net margin of 45.25% compared to Tarsus Pharmaceuticals' net margin of -9.02%. CorMedix's return on equity of 45.57% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

In the previous week, Tarsus Pharmaceuticals had 4 more articles in the media than CorMedix. MarketBeat recorded 4 mentions for Tarsus Pharmaceuticals and 0 mentions for CorMedix. Tarsus Pharmaceuticals' average media sentiment score of 0.64 beat CorMedix's score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
CorMedix	Neutral
Tarsus Pharmaceuticals	Positive

Summary

CorMedix beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does CorMedix compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

CorMedix has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
CorMedix	$311.71M	2.10	$163.05M	$2.13	3.92

CorMedix has a net margin of 45.25% compared to Vera Therapeutics' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
CorMedix	45.25%	45.57%	24.76%

Vera Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

In the previous week, Vera Therapeutics had 10 more articles in the media than CorMedix. MarketBeat recorded 10 mentions for Vera Therapeutics and 0 mentions for CorMedix. Vera Therapeutics' average media sentiment score of 0.61 beat CorMedix's score of 0.00 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Vera Therapeutics	Positive
CorMedix	Neutral

Vera Therapeutics currently has a consensus target price of $78.00, suggesting a potential upside of 141.56%. CorMedix has a consensus target price of $15.00, suggesting a potential upside of 79.43%. Given Vera Therapeutics' higher probable upside, equities analysts plainly believe Vera Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by insiders. Comparatively, 3.5% of CorMedix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

CorMedix beats Vera Therapeutics on 8 of the 14 factors compared between the two stocks.

How does CorMedix compare to Immunome?

Immunome (NASDAQ:IMNM) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

CorMedix has a net margin of 45.25% compared to Immunome's net margin of 0.00%. CorMedix's return on equity of 45.57% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
CorMedix	45.25%	45.57%	24.76%

In the previous week, Immunome had 3 more articles in the media than CorMedix. MarketBeat recorded 3 mentions for Immunome and 0 mentions for CorMedix. Immunome's average media sentiment score of 0.25 beat CorMedix's score of 0.00 indicating that Immunome is being referred to more favorably in the media.

Company	Overall Sentiment
Immunome	Neutral
CorMedix	Neutral

CorMedix has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	303.20	-$212.39M	-$2.38	N/A
CorMedix	$311.71M	2.10	$163.05M	$2.13	3.92

Immunome has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

44.6% of Immunome shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 7.2% of Immunome shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Immunome presently has a consensus target price of $33.17, indicating a potential upside of 78.51%. CorMedix has a consensus target price of $15.00, indicating a potential upside of 79.43%. Given CorMedix's higher probable upside, analysts plainly believe CorMedix is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Immunome and CorMedix tied by winning 8 of the 16 factors compared between the two stocks.

Get CorMedix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRMD vs. The Competition

Export

Metric	CorMedix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$655.86M	$3.34B	$6.66B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.55%
P/E Ratio	3.92	10.33	20.31	21.86
Price / Sales	2.10	300.34	516.18	112.47
Price / Cash	4.09	51.45	26.99	37.22
Price / Book	1.63	7.97	10.24	6.66
Net Income	$163.05M	$23.89M	$3.57B	$337.55M
7 Day Performance	-0.95%	-6.96%	-1.28%	-2.52%
1 Month Performance	5.56%	-2.80%	1.38%	-0.03%
1 Year Performance	-40.20%	36.80%	23.93%	25.34%

CorMedix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRMD CorMedix	2.5897 of 5 stars	$8.36 -2.1%	$15.00 +79.4%	-40.2%	$655.86M	$311.71M	3.92	30
MLYS Mineralys Therapeutics	3.8705 of 5 stars	$31.11 -1.2%	$49.33 +58.6%	+47.0%	$2.60B	N/A	N/A	28
IDYA IDEAYA Biosciences	2.7197 of 5 stars	$28.94 -1.8%	$50.69 +75.1%	+30.2%	$2.59B	$218.71M	N/A	80	Analyst Forecast
TARS Tarsus Pharmaceuticals	3.1172 of 5 stars	$58.93 -0.8%	$90.67 +53.9%	+35.0%	$2.56B	$451.36M	N/A	50	Analyst Upgrade
VERA Vera Therapeutics	3.3304 of 5 stars	$33.94 -4.4%	$79.00 +132.8%	+42.2%	$2.55B	N/A	N/A	40	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRMD) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CorMedix (CRMD) Competitors

CRMD vs. MLYS, IDYA, TARS, VERA, and IMNM

How does CorMedix compare to Mineralys Therapeutics?

Summary

How does CorMedix compare to IDEAYA Biosciences?

Summary

How does CorMedix compare to Tarsus Pharmaceuticals?

Summary

How does CorMedix compare to Vera Therapeutics?

Summary

How does CorMedix compare to Immunome?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CorMedix (CRMD) Competitors

CRMD vs. MLYS, IDYA, TARS, VERA, and IMNM

How does CorMedix compare to Mineralys Therapeutics?

Does the media prefer CRMD or MLYS?

Which has more risk and volatility, CRMD or MLYS?

Is CRMD or MLYS more profitable?

Which has higher earnings & valuation, CRMD or MLYS?

Do insiders & institutionals believe in CRMD or MLYS?

Do analysts recommend CRMD or MLYS?

Summary

How does CorMedix compare to IDEAYA Biosciences?

Do analysts recommend IDYA or CRMD?

Which has stronger valuation & earnings, IDYA or CRMD?

Which has more risk and volatility, IDYA or CRMD?

Is IDYA or CRMD more profitable?

Do insiders & institutionals have more ownership in IDYA or CRMD?

Does the media prefer IDYA or CRMD?

Summary

How does CorMedix compare to Tarsus Pharmaceuticals?

Do institutionals & insiders hold more shares of CRMD or TARS?

Do analysts recommend CRMD or TARS?

Which has more risk & volatility, CRMD or TARS?

Which has stronger earnings & valuation, CRMD or TARS?

Is CRMD or TARS more profitable?

Does the media refer more to CRMD or TARS?

Summary

How does CorMedix compare to Vera Therapeutics?

Which has stronger earnings & valuation, VERA or CRMD?

Is VERA or CRMD more profitable?

Which has more risk and volatility, VERA or CRMD?

Does the media favor VERA or CRMD?

Do analysts prefer VERA or CRMD?

Do institutionals and insiders hold more shares of VERA or CRMD?

Summary

How does CorMedix compare to Immunome?

Is IMNM or CRMD more profitable?

Does the media favor IMNM or CRMD?

Which has stronger valuation and earnings, IMNM or CRMD?

Which has more volatility & risk, IMNM or CRMD?

Do institutionals & insiders have more ownership in IMNM or CRMD?

Do analysts rate IMNM or CRMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools